title: Antianginal Efficacy of Ivabradine in Patients With History of Coronary Revascularization.
abstract: Although coronary revascularization procedures are widely performed in patients with coronary artery disease (CAD), angina is often reported, even after such procedures. This study evaluated the antianginal efficacy and effect of ivabradine treatment on quality of life (QOL) in patients with CAD and history of coronary revascularization. This is a post hoc analysis (926 post-revascularization patients) of a prospective, noninterventional study, which included 2403 patients with CAD and stable angina. The data were recorded at baseline, at 1 month and 4 months after inclusion. After ivabradine administration, mean number of anginal events decreased from 2.2 ± 2.3 (median: 2.0, minimum: 0.0, maximum: 21.0, range: 21.0) to 0.3 ± 0.6 (median: 0.0, minimum: 0.0, maximum: 7.0, range: 7.0) times/week (P < .001), while nitroglycerin consumption decreased from 1.5 ± 2.2 (median: 1.0, minimum: 0.0, maximum: 20.0, range: 20.0) to 0.1 ± 0.4 times/week (median: 0.0, minimum: 0.0, maximum: 5.0, range: 5.0; P < .001). Quality of life improved at study completion compared to baseline (P < .001). Ivabradine addition on top of optimal individualized dose of β-blockers is associated with decreased anginal events and improvement in QOL in patients with stable angina and history of coronary revascularization.
authors.affiliation: Cardiology Department, George Papanikolaou General Hospital, Thessaloniki, Greece.
authors.forename: J
authors.initials: J
authors.lastname: Zarifis
authors.affiliation: Medical Department, Servier Hellas Pharmaceuticals Ltd, Athens, Greece.
authors.forename: V
authors.initials: V
authors.lastname: Grammatikou
authors.affiliation: Medical Department, Servier Hellas Pharmaceuticals Ltd, Athens, Greece emmanouil.kallistratos@servier.com.
authors.forename: M
authors.initials: M
authors.lastname: Kallistratos
authors.affiliation: First Cardiology Department, Korgialeneio-Benakeio E.E.S. General Hospital, Athens, Greece.
authors.forename: A
authors.initials: A
authors.lastname: Katsivas
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D060050:Angina, Stable / Q000188:drug therapy; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D003324:Coronary Artery Disease / Q000188:drug therapy*; D004359:Drug Therapy, Combination / Q000379:methods; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D000077550:Ivabradine / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D062645:Percutaneous Coronary Intervention; D011788:Quality of Life
chemical_list: D000319:Adrenergic beta-Antagonists; D002317:Cardiovascular Agents; D000077550:Ivabradine
keywords: ivabradine; quality of life; stable angina